Stock comparison
Genmab A/S
Pacira BioSciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
PCRX
Pacira BioSciences
Market cap
$918.47M
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | PCRX | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 45D | GMAB |
| Benjamin Graham | 64C | 55D | GMAB |
| Philip Fisher | 48D | 41D | GMAB |
| Peter Lynch | 25F | 16F | GMAB |
| Joel Greenblatt | 76B | 43D | GMAB |
| Charlie Munger | 68C | 41D | GMAB |
| Terry Smith | 71C | 41D | GMAB |
Side-by-side metrics
| Metric | GMAB | PCRX |
|---|---|---|
| Market cap | $16.5B | $918.47M |
| P/E (TTM) | 6.2x | 181.4x |
| EV/EBIT | 12.0x | 35.2x |
| ROIC (TTM) | 43.78% | 0.8% |
| Gross margin | 93.88% | 79.34% |
| Net margin | 18.23% | 0.7% |
| Revenue CAGR 5y | -18.45% | 7.62% |
| EPS CAGR 5y | -23.48% | -35.94% |
| Debt / Equity | 0.1x | 0.6x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 0.8%+98%
- P/E (TTM)6.2xvs 181.4x+97%
- Net margin18.23%vs 0.7%+96%
- Market cap$16.5Bvs $918.47M+94%
PCRX leads on
- Revenue CAGR 5y7.62%vs -18.45%+141%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.